Afferent Header no flash

Afferent Pharmaceuticals

Composite Afferent approach illustration

Afferent Pharmaceuticals is a clinical-stage biopharmaceutical company leading the development of first-in-class, proprietary, small molecule compounds that target P2X3 receptors for the treatment of chronic pain, respiratory and urological conditions.  P2X3 receptors are novel targets, highly specific to unmyelinated, small diameter C fiber afferent (or sensory) nerves that have dense innervations in visceral organs, skin and joints and which transmit pain and other sensations of organ function.

Afferent’s singular focus and industry-leading position on P2X3 antagonism enables the Company to widely explore this novel mechanism of action and evaluate its utility in a broad range of indications.  These indications, being explored in multiple Phase 2 proof clinical studies, include chronic pain in the joints, hyperresponsive airways (chronic cough, asthma) and bladder pain and hyperactivity (interstitial cystitis/bladder pain syndrome (IC/BPS), overactive bladder).

Summary of current development activities